Alnylam Pharmaceuticals (ALNY) Non-Current Deffered Revenue (2009 - 2024)
Alnylam Pharmaceuticals posted quarterly Non-Current Deffered Revenue of $1.0 million for Q3 2024, down 99.48% year-on-year from $196.1 million in Q4 2023, and down 57.87% on a QoQ basis from $2.4 million in Q2 2024.
Alnylam Pharmaceuticals (ALNY) has 16 years of Non-Current Deffered Revenue data on file, last reported at $1.0 million in Q3 2024.
- For the quarter ending Q3 2024, Non-Current Deffered Revenue fell 99.48% year-over-year to $1.0 million; the trailing twelve-month figure through Sep 2024 stood at $1.0 million (down 99.48% YoY), and the FY2023 full-year result was $188.2 million, down 2.9% from the prior year.
- Non-Current Deffered Revenue for Q3 2024 stood at $1.0 million, down from $2.4 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $306.1 million in Q1 2020 and bottomed at $1.0 million in Q3 2024.
- The 5-year median for Non-Current Deffered Revenue is $191.3 million (2023), against an average of $180.9 million.
- The widest annual swing landed in 2020, when Non-Current Deffered Revenue jumped 63942.68%; it then sank 99.48% in 2024.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $225.1 million in 2020, then slumped by 32.31% to $152.4 million in 2021, then grew by 27.19% to $193.8 million in 2022, then fell by 2.9% to $188.2 million in 2023, then slumped by 99.46% to $1.0 million in 2024.
- The last three Non-Current Deffered Revenue figures came in at $1.0 million (Q3 2024), $2.4 million (Q2 2024), and $185.5 million (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Mar 31, 2024 | 185.51 Mn |
| Dec 31, 2023 | 188.18 Mn |
| Sep 30, 2023 | 196.09 Mn |
| Jun 30, 2023 | 194.13 Mn |
| Mar 31, 2023 | 191.26 Mn |
| Dec 31, 2022 | 193.79 Mn |
| Sep 30, 2022 | 132.93 Mn |
| Jun 30, 2022 | 175.34 Mn |
| Mar 31, 2022 | 157.67 Mn |
| Dec 31, 2021 | 152.36 Mn |
| Sep 30, 2021 | 177.12 Mn |
| Jun 30, 2021 | 202.39 Mn |
| Mar 31, 2021 | 208.12 Mn |
| Dec 31, 2020 | 225.09 Mn |
| Sep 30, 2020 | 265.71 Mn |
| Jun 30, 2020 | 281.53 Mn |
| Mar 31, 2020 | 306.12 Mn |
| Dec 31, 2019 | 318.38 Mn |
| Jun 30, 2019 | 313.89 Mn |
| Mar 31, 2019 | 478,000.00 |
| Dec 31, 2018 | 57.92 Mn |
| Sep 30, 2018 | 1.62 Mn |
| Jun 30, 2018 | 4.52 Mn |
| Mar 31, 2018 | 10.82 Mn |
| Dec 31, 2017 | 43.08 Mn |
| Sep 30, 2017 | 38.36 Mn |
| Jun 30, 2017 | 42.08 Mn |
| Mar 31, 2017 | 8.01 Mn |
| Dec 31, 2016 | 49.39 Mn |
| Sep 30, 2016 | 8.30 Mn |
| Jun 30, 2016 | 6.52 Mn |
| Mar 31, 2016 | 53.95 Mn |
| Dec 31, 2015 | 52.97 Mn |
| Sep 30, 2015 | 5.31 Mn |
| Jun 30, 2015 | 5.31 Mn |
| Mar 31, 2015 | 46.57 Mn |
| Dec 31, 2014 | 5.01 Mn |
| Sep 30, 2014 | 20.03 Mn |
| Jun 30, 2014 | 3.10 Mn |
| Mar 31, 2014 | 37.67 Mn |
| Dec 31, 2013 | 93.39 Mn |
| Sep 30, 2013 | 3.25 Mn |
| Jun 30, 2013 | 97.64 Mn |
| Mar 31, 2013 | 105.98 Mn |
| Dec 31, 2012 | 100.87 Mn |
| Sep 30, 2012 | 85.03 Mn |
| Mar 31, 2012 | 3.20 Mn |
| Dec 31, 2011 | 3.73 Mn |
| Sep 30, 2011 | 84.81 Mn |
| Jun 30, 2011 | 100.12 Mn |
| Mar 31, 2011 | 2.87 Mn |
| Dec 31, 2010 | 129.97 Mn |
| Sep 30, 2010 | 149.67 Mn |
| Jun 30, 2010 | 2.54 Mn |
| Dec 31, 2009 | 189.88 Mn |